Theracryf Plc

EVG

GB00BSVYN304

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:14 2024-05-21 am EDT			5-day change	1st Jan Change
0.75 ^GBX	0.00%		0.00%	-53.12%

Apr. 26	Evgen Pharma plc will Change its Ticker to TCF from EVG	CI
Apr. 26	Evgen Pharma plc will Change its Name to TheraCryf plc	CI

Evgen Pharma plc Announces Resignation of Mark Wyatt as Non-Executive Director

April 03, 2017 at 09:15 am EDT

Evgen Pharma plc announced that Non-Executive Director Mark Wyatt is stepping down from the board with immediate effect.

Latest news about Theracryf Plc

Evgen Pharma plc will Change its Ticker to TCF from EVG	Apr. 26	CI
Evgen Pharma plc will Change its Name to TheraCryf plc	Apr. 26	CI
Norcros sells Johnson Tiles UK; Trifast trading well	Apr. 25	AN
Northcoders launches bootcamp; Schroder invests	Apr. 04	AN
Evgen Pharma Concludes Retail Offer of Shares	Apr. 04	MT
Evgen Pharma Signs Takeover Deal with Chronos Therapeutics; Raises Capital Via Share Issue, Subscription	Mar. 20	MT
EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat	Mar. 19	AN
Evgen Pharma plc agreed to acquire Chronos Therapeutics Ltd. from group of shareholders for £3.4 million.	Mar. 18	CI
Evgen Pharma finds evidence of SFX-01 activity in colon cancer models	Feb. 27	AN
Evgen Pharma plc Announces That the Laboratories of Professor Grace Chen, Associate Professor Justin Colacino, and Professor Duxin Sun At the University of Michigan, Usa Have Observed Activity of Sfx-01 in Models of Colon Cancer	Feb. 27	CI
Evgen Pharma shares up on studies into SFX-01 product progressing well	Feb. 19	AN
Evgen Pharma plc Announces That the Laboratory of Dr Marjolein Geurts, Neuro-Oncologist At the Erasmus University Medical Centre Has Observed Continuing Activity of Sfx-01 in Gbm Cells	Feb. 19	CI
Apax opts against lifting offer; DCI enters loan deal	Feb. 09	AN
FTSE 100 falls at end of tepid week	Feb. 09	AN
Evgen Pharma Issues Notice of Dispute to Stalicla Over Missed Milestone Payment	Feb. 09	MT
Evgen partner raises USD17.4 million to support pipeline	Jan. 16	AN
Evgen Pharma plc announced that it has received $17.4 million in funding from Stalicla SA	Jan. 15	CI
Evgen appoints Toni Hanninen as permanent CFO	Dec. 22	AN
Evgen Pharma Interim CFO to Assume Post Permanently	Dec. 22	MT
Evgen Pharma plc Appoints Toni hänninen as Permanent Chief Financial Officer, Effective 1 January 2024	Dec. 22	CI
Evgen Pharma plc Announces Changes to its Board	Dec. 22	CI
Acuity RM wins contract; Georgia Capital ups earnings	23-10-31	AN
Earnings Flash (EVG.L) EVGEN PHARMA Reports Fiscal H1 Revenue GBP396,000	23-10-31	MT
Earnings Flash (EVG.L) EVGEN PHARMA Reports Fiscal H1 Loss GBX-0.53	23-10-31	MT
Evgen Pharma plc Reports Earnings Results for the Half Year Ended September 30, 2023	23-10-31	CI

Theracryf PLC, formerly Evgen Pharma plc, is a clinical-stage therapeutics company. The Company is engaged in developing a new generation of therapeutics in oncology and behavioral brain disorders. Its pipeline and lead compound SFX-01 is derived from its proprietary Sulforadex technology. Its Sulforadex technology synthesizes sulforaphane into an active, stable, and solid form pharmaceutical ingredient, unlocking its medical and commercial potential. SFX-01 is a complex of sulforaphane and alpha-cyclodextrin formulated as a stable tablet. The Company has a candidate orexin 1 antagonist at late preclinical stage targeting addictive behaviors. It also has a candidate molecule DAT inhibitor at late preclinical stage targeting fatigue and narcolepsy.

Sector

Biotechnology & Medical Research

Calendar

2024-05-28 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Theracryf Plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
THERACRYF PLC	-53.12%	4.08M
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	114B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.22B
ARGENX SE	-3.99%	21.28B
BEIGENE, LTD.	-7.19%	17.51B
WUXI APPTEC CO., LTD.	-39.93%	17.17B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.14B
SAREPTA THERAPEUTICS, INC.	+33.90%	12.2B
LEGEND BIOTECH CORPORATION	-28.60%	7.83B

Bio Therapeutic Drugs

Theracryf Plc

Equities

EVG

GB00BSVYN304

Biotechnology & Medical Research

Evgen Pharma plc Announces Resignation of Mark Wyatt as Non-Executive Director

Latest news about Theracryf Plc

Chart Theracryf Plc

Company Profile

Income Statement Evolution

Ratings for Theracryf Plc

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs